echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Nat Commun: Specificity of the intestinal microbial co-abundance network in inflammatory bowel disease and obesity.

    Nat Commun: Specificity of the intestinal microbial co-abundance network in inflammatory bowel disease and obesity.

    • Last Update: 2020-08-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 11, 2020, a team of Professor Fu Jingyuan from the University of Groningen, the Netherlands, published an article entitled Gut Microbial co-abundance networks show specificity in the place of the website bowel disease and obesity at Nature Communications.
    intestinal microbiome is an ecosystem involved in complex interactions.
    , researchers' understanding of the role of the gut microbiome in health and disease depends largely on the abundance of different microorganisms, and little is known about the role of microbial interactions in the context of human diseases, " he said.
    Here, the researchers used 2,379 metagenomes from four human queues to build and compare microbial co-abundance networks: an inflammatory bowel disease (IBD) queue, an obesity queue, and two population-based queues.
    researchers found significant differences in the intensity of 38.6 percent of species and 64.3 percent of pathocy, 113 species and 1,050 pathopions showed IBD-specific effects, and 281 path-co-abundances showed obesity-specific effects.
    researchers could also replicate these IBD microbial co-abundances in longitudinal data from the IBD queue that integrates the Human Microbiome (iHMP-IBD) project.
    researchers' study identified several key species and path paths of IBD and obesity, and provided evidence that changes in microbial abundance in disease can affect their co-abundance, which has enriched researchers' current understanding of microbial disorders in disease.
    analysis of the intestinal microbial co-abundance network shows that microbial composition and functional maps overlap to a large extent, although the researchers observed significant changes in the composition of species in the IBD queue.
    134 bacterial species and 343 microbial paths present in at least one of the samples in the queue were included in the microbial network inference.
    researchers combined the SparkC and SpiecEasi methods to establish a microbial co-abundance relationship.
    For species networks, the researchers identified 2,604 common abundances in the LLD queue, 1,591 common abundances in the 500FG queue, 1,107 common abundances in the 300OB queue, and 2,554 common abundances in the IBD queue, resulting in a total of 3,454 unique species common abundances.
    note that 82.1 per cent of species co-abundance also showed co-emergance.
    for paths, the total abundance ranges from 37,279 for 500FG to 40,699 for LLD, resulting in a total of 43,355 unique path co-abundances.
    Different microbial co-abundances were reflected in the abundance levels when amplifying 100 species and 304 paths involving variable co-abundance, and significant differences in abundance levels between the queues were also shown in 76% of species and 84% of paths.
    means that variable co-abundance relationships are largely reflected in different microbial abundances.
    researchers summarized the number of differences and abundance between species from the same genus or from different genus.
    The genus with the greatest co-abundance is streptococcus, which not only observed a large number of different co-abundances between different streptococcus, but also a large number of different co-abundances between streptococcus and other genus species, such as fungi and Velococcus.
    in the IBD queue, the species of streptococcus was higher, in line with previous studies.
    similar observations have been made of path co-abundance, particularly amino acid biosynthesis paths, which show diversity not only within themselves, but also in the various paths associated with nucleoside and nucleotide biosynthesis.
    Specific microbial co-abundance in disease queues Researchers analyzed whether variable co-abundance relationships were driven by specific queues, i.e. whether the strength of queue abundance in one queue was significantly different from the strength of queue abundance in the other three queues.
    Interestingly, group-specific co-abundance in disease queues was significantly rich compared to group-based queues: 113 (94%) species co-abundance and 1050 (72%) path-to-path co-abundance and IBD co-abundance Heteroglycero-related, 281 (19.4%) path co-abundances were associated with 300OB cohort specificity, compared with only 3 species and 117 paths of common abundance relationship exclusive to population-based queue LLD and 500FG.
    the researchers' results underscore that the common abundance of microorganisms depends on the host's health and disease status. The microbial co-abundance network in
    IBD replicated the IBD network in the Integrated Human Microbiome Project (iHMP-IBD) queue: 2,554 species and 37,699 pathogenic co-abundances were established in the researchers' IBD queue, and the researchers were able to assess the total abundance and 37,106 total abundance of 27,106 IBD individuals in the iHMP-IBD39. The relatively low replication rate of
    species common abundance was largely a power issue, as the researchers also observed no significant difference in common abundance strength between the researchers' IBD and iHMP-IBD queues of 1705 (81.6%) species and 24,165 (65.1%) path paths.
    then, the researchers compared the IBD network between the first and last points in the iHMP-IBD queue (between one year and one year apart), replicating 90.6 percent of species and 99.6 percent of pathoamus abundance.
    suggests that the researchers' estimates of IBD co-abundance intensity were largely repeatable in different queues and stable over time.
    the microbial network of IBD to disease characteristics: previous studies have shown that observed differences in microbial abundance can be explained by certain disease characteristics of IBD14.
    , the researchers hypothesed that the same-origin abundance relationship might also be the case.
    The researchers assessed whether IBD co-abundance was associated with disease sub-types (UC, n?189) and Crohn's disease (CD, n?276), the disease site (back intestine (n?212) and colon (n?286) and disease activity (n?121) and non-inflammatory (n?377).
    Most co-abundance relationships are relevant between disease characteristics, and only a few show significant differences in FDR-lt;0.05, i.e. 16 co-abundances associated with disease sub-types and 8 co-abundances associated with location.
    the total abundance of the path, 91 were associated with disease substypes, 24 were related to location, and 3 were related to activity.
    five of these co-abundance relationships were associated with an important butyric acid-producing bacteria, uc than cd, which showed a stronger co-abundance relationship.
    Drug-related IBD microbial network: The researchers further tested whether drug use affected microbial co-abundance because IBD patients used antibiotics (20.0%) and proton pump inhibitors (PPI; 26.5%) higher than the general population (1.1% and 8.4%). the
    researchers found no significant difference in species co-abundance between antibiotic users and non-antibiotic users, while 1049 (3.7%) pathway co-abundance relationships showed statistically significant differences between PPI users and non-users, especially with isoprene biosynthesis and methyl erythropoietin phosphoric acid pathways. key species and pathways in
    IBD: When comparing microbial co-abundance in IBD with three other cohorts, the researchers identified 113 species of co-abundance and 1,050 path-co-abundance, showing significantly different effects than the other three.
    , the researchers then assessed whether these IBD-specific co-abundances were highly associated with specific paths or species that might be associated with the disease, and the researchers' analysis identified three key species and four key paths of IBD.
    the key strains are E. coli, herbillus and Grevinitz line bacteria.
    E. coli and methicillus have previously been associated with IBD14, 41-45.
    Interestingly, E. coli showed a positive co-abundance relationship with species with pro-inflammatory properties, such as deformed streptococcus, and a negative co-abundance relationship with species with anti-inflammatory properties, such as Puthious.
    paths to IBD include C1 compound utilization and assimmification paths, two vitamin biosynthesis paths, and amino acid biosynthesis paths.
    the most critical functional path to IBD is the restorative TCA loop path (P23-pwy), which has 76 IBD-specific co-abundances, 94.7% of which are replicated in the iHMP-IBD queue.
    reductive TCA cycle is a fixed path of carbon dioxide and has been considered the original path for the production of organic molecules for the biosynthesis of sugars, lipids, amino acids, tantalum and cauliflower.
    although the abundance of this path in IBD is high, the co-abundance relationship of this path in IBD (r?0.1) is weaker than that of other queues (r?0.3).
    researchers found that 18.8 percent of the biosynthetic pathopathy in IBD patients was contributed by E. coli, twice as many as in the two population groups.
    findings suggest that E. coli is an important contributor to the biosynthesis of vegetables in IBD, which may promote the growth of other microorganisms.
    fact, the researchers' study also revealed that E. coli is a key species of IBD, showing a specific co-abundance relationship with 15 species.
    , there is a strong positive correlation between the types of streptococcus associated with inflammation, including deformed streptococcus, foretress streptococcus, and baby streptococcus.
    , the correlation between vegetable biosynthesis and streptococcus species in IBD patients was higher than in other cohorts.
    of microbial co-abundance network 300OB network in 300OB in obese individuals with LLD: 1107 species and 37,886 pathpy co-abundance were detected in the 300OB queue.
    Most of the 134 obese people in the LLD queue with these estimated co-abundance intensity were replicable, with 991 (89.5%) species co-abundance and 32,963 (87.0%) pathopity showing no difference.
    microbial networks linked to obesity-related diseases: The 300OB queue was set up to study cardiovascular disease in obese individuals, including 139 patients with atherosclerotic plaques and 159 obesity controls.
    , 35 300 OB participants had diabetes.
    here, the researchers observed only three species associated with cardiovascular disease, all of which showed greater co-abundance in patients with plaques than in patients without plaques.
    key paths to obesity: When the researchers compared microbial co-abundance in 300OB and three other queues, they identified 281 pathpy co-abundances that showed significantly different effects, namely obesity-specific co-abundance.
    path to obesity is the degradation of urea, which shows the obesity-specific co-abundance relationship of 85 paths.
    is one of the active ingredients in a variety of plants, such as yam, and has been found to promote insulin secretion and lower blood sugar.
    its degradation product, procterate, inhibits in the acetaminophen/winter amino acid.
    in line with this, the researchers found a strong negative correlation between urethra degradation pathways and biosynthesis pathways of urethyl acetic acid/tiantianine (including lysine, hyperserine, methionine, suline and isolysine), and biosynthetic pathways of urethrin, both of which were positively associated with anthrobetic blood sugar levels and negatively associated with insulin levels on an empty stomach.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.